MetaADEDB 2.0 @ LMMD
telavancin
(GSSIWSIRBWAZHG-ACOPVEIWSA-N)
Structure
SMILES
CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@@H](O[C@@H]([C@H]([C@@H]2O)O)CO)Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]([C@@H](c4ccc(O3)c(Cl)c4)O)NC(=O)[C@@H](CC(C)C)NC)c3ccc(c(c3)c3c([C@H](NC2=O)C(=O)O)cc(c(c3O)CNCP(=O)(O)O)O)O)O[C@H]([C@H]1O)C.Cl
Molecular Formula:
C80H107Cl3N11O27P
Molecular Weight:
1792.100
Log P:
7.7930
Hydrogen Bond Acceptor:
38
Hydrogen Bond Donor:
24
TPSA:
607.9
CAS Number(s):
560130-42-9
Synonym(s)
1.
telavancin
2.
TD 6424
3.
TD-6424
4.
TD6424
5.
Vibativ
6.
telavancin hydrochloride
External Link(s)
MeSHC487637
PubChem Compound9812715
ChEBI71226
CHEMBLCHEMBL3301680
KEGGdr:D06057
Therapeutic Target DatabaseD02IJB
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Blood creatinine increasedFAERS: 5US FAERS
2Cardiac ArrestFAERS: 4US FAERS
3ChillsFAERS: 4US FAERS
4Lip swellingFAERS: 4US FAERS
5NauseaFAERS: 4US FAERS
6ThrombocytopeniaFAERS: 4US FAERS
7Accidental exposureFAERS: 3US FAERS
8AngioedemaFAERS: 3US FAERS
9AphoniaFAERS: 3US FAERS
10Burning sensationFAERS: 3US FAERS
11Chest PainFAERS: 3US FAERS
12ErythemaFAERS: 3US FAERS
13Oropharyngeal painFAERS: 3US FAERS
14Tongue blisteringFAERS: 3US FAERS
15TremorFAERS: 3US FAERS
16Acute kidney injuryFAERS: 2US FAERS
17ArthralgiaFAERS: 2US FAERS
18Blood glucose increasedFAERS: 2US FAERS
19Chest discomfortFAERS: 2US FAERS
20Disease ProgressionFAERS: 2US FAERS
21LeukopeniaFAERS: 2US FAERS
22Myocardial InfarctionFAERS: 2US FAERS
23Neck PainFAERS: 2US FAERS
24NeutropeniaFAERS: 2US FAERS
25Neutrophil count decreasedFAERS: 2US FAERS
26Renal tubular necrosisFAERS: 2US FAERS
27VomitingFAERS: 2US FAERS
28White blood cell count decreasedFAERS: 2US FAERS
29AgeusiaFAERS: 1US FAERS
30Alanine Aminotransferase IncreasedFAERS: 1US FAERS
31Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
32AstheniaFAERS: 1US FAERS
33Back PainFAERS: 1US FAERS
34Blood alkaline phosphatase increasedFAERS: 1US FAERS
35DeafnessFAERS: 1US FAERS
36DehydrationFAERS: 1US FAERS
37Device related sepsisFAERS: 1US FAERS
38DizzinessFAERS: 1US FAERS
39DysgeusiaFAERS: 1US FAERS
40DyspepsiaFAERS: 1US FAERS
41EpistaxisFAERS: 1US FAERS
42FatigueFAERS: 1US FAERS
43Feeling abnormalFAERS: 1US FAERS
44HeadacheFAERS: 1US FAERS
45HypersensitivityFAERS: 1US FAERS
46InfectionFAERS: 1US FAERS
47LethargyFAERS: 1US FAERS
48Lip exfoliationFAERS: 1US FAERS
49Macular degenerationFAERS: 1US FAERS
50OnycholysisFAERS: 1US FAERS
51OverdoseFAERS: 1US FAERS
52PainFAERS: 1US FAERS
53Post procedural infectionFAERS: 1US FAERS
54Pulmonary EmbolismFAERS: 1US FAERS
55Respiratory FailureFAERS: 1US FAERS
56RhabdomyolysisFAERS: 1US FAERS
57SwellingFAERS: 1US FAERS
58Transaminases increasedFAERS: 1US FAERS
59Unevaluable eventFAERS: 1US FAERS
60UrticariaFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.